Vermillion this week showed preliminary data from its work with Johns Hopkins University School of Medicine to identify protein biomarkers that could improve the accuracy of its OVA1 test for ovarian cancer.

According to the company, the study, which was presented at the 42nd Annual Meeting on Women's Cancer of the Society of Gynecological Oncologists, examined more than 20 candidate biomarkers, identifying three that added information to CA125, the protein biomarker conventionally used in ovarian cancer diagnosis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.